Biological Predictors of Cervical Cancer Response to Radiation Therapy

Seminars in Radiation Oncology

Volumn 22, Issue 2, 2012, Pages 143-150

  Klopp, Ann H ^a   Eifel, Patricia J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; CISPLATIN; COPPER DIACETYL DI[N(4)METHYLTHIOSEMICARBAZONE] CU 64; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUORODEOXYGLUCOSE; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; RADIOPHARMACEUTICAL AGENT; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANEMIA; BLOOD VESSEL PARAMETERS; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CELL SURVIVAL; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; EX VIVO STUDY; EXTERNAL BEAM RADIOTHERAPY; GENE EXPRESSION PROFILING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; HYPOXIA; HYSTERECTOMY; INTERSTITIAL TUMOR PRESSURE; LEUKOCYTOSIS; MOLECULARLY TARGETED THERAPY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; POST TREATMENT SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; RECURRENCE RISK; REVIEW; THROMBOCYTOSIS; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VASCULAR DENSITY; WART VIRUS;

FEMALE; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; UTERINE CERVICAL NEOPLASMS;

EID: 84857563152     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.12.009     Document Type: Review

References (67)

1. Eifel P.J., Jhingran A., Levenback C.F., et al. Predictive value of a proposed subclassification of stages I and II cervical cancer based on clinical tumor diameter. Int J Gynecol Cancer 2009, 19:2-7.
2. Horiot J.C., Pigneux J., Pourquier H., et al. Radiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: A French cooperative study of 1383 cases. Int J Radiat Oncol Biol Phys 1988, 14:605-611.
3. Logsdon M.D., Eifel P.J. Figo IIIB squamous cell carcinoma of the cervix: An analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. Int J Radiat Oncol Biol Phys 1999, 43:763-775.
4. Perez C.A., Grigsby P.W., Chao K.S., et al. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 1998, 41:307-317.
5. Eifel P.J. Concurrent chemotherapy and radiation: A major advance for women with cervical cancer. J Clin Oncol 1999, 17:1334-1335.
6. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 2001, 358:781-786.
7. Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst Rev 2004, CD001774.
8. Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000, 18:1606-1613.
9. Duenas-Gonzalez A., Zarba J.J., Patel F., et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011, 29:1678-1685.
10. Delgado G., Bundy B., Zaino R., et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol 1990, 38:352-357.
11. Viswanathan A.N., Deavers M.T., Jhingran A., et al. Small cell neuroendocrine carcinoma of the cervix: Outcome and patterns of recurrence. Gynecol Oncol 2004, 93:27-33.
12. Monk B.J., Tian C., Rose P.G., et al. Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma?. Analysis of two Gynecologic Oncology Group (GOG) trials. Gynecol Oncol 2007, 105:427-433.
13. Eifel P.J., Burke T.W., Morris M., et al. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995, 59:38-44.
14. Rotman M., Sedlis A., Piedmonte M.R., et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: Follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 2006, 65:169-176.
15. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998, 48:149-156.
16. Hockel M., Schlenger K., Aral B., et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56:4509-4515.
17. Fyles A., Milosevic M., Hedley D., et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002, 20:680-687.
18. Grigsby P.W., Winter K., Wasserman T.H., et al. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: Final results of RTOG 80-05. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1999, 44:513-517.
19. Overgaard J., Bentzen S.M., Kolstad P., et al. Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1989, 16:1069-1072.
20. Milosevic M., Fyles A., Hedley D., et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 2001, 61:6400-6405.
21. Milosevic M., Fyles A., Hedley D., et al. The human tumor microenvironment: Invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004, 14:249-258.
22. Randall L.M., Monk B.J., Moon J., et al. Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: A Southwest Oncology Group study. Gynecol Oncol 2010, 119:417-421.
23. West C.M., Davidson S.E., Roberts S.A., et al. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer 1993, 68:819-823.
24. West C.M., Davidson S.E., Roberts S.A., et al. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 1997, 76:1184-1190.
25. Cooper R.A., Wilks D.P., Logue J.P., et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 1998, 4:2795-2800.
26. Cooper R.A., West C.M., Wilks D.P., et al. Tumour vascularity is a significant prognostic factor for cervix carcinoma treated with radiotherapy: Independence from tumour radiosensitivity. Br J Cancer 1999, 81:354-358.
27. Randall L.M., Monk B.J., Darcy K.M., et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2009, 112:583-589.
28. Hernandez E., Donohue K.A., Anderson L.L., et al. The significance of thrombocytosis in patients with locally advanced cervical carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2000, 78:137-142.
29. Mabuchi S., Matsumoto Y., Isohashi F., et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol Oncol 2011, 122:25-32.
30. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999, 86:1528-1536.
31. Thomas G. The effect of hemoglobin level on radiotherapy outcomes: The Canadian experience. Semin Oncol 2001, 28:60-65.
32. Bush R.S. The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 1986, 12:2047-2050.
33. Thomas G., Ali S., Hoebers F.J., et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008, 108:317-325.
34. Xue F., Lin L.L., Dehdashti F., et al. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol 2006, 101:147-151.
35. Grigsby P.W. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging 2008, 8:146-155.
36. Kidd E.A., Spencer C.R., Huettner P.C., et al. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer 2009, 115:3548-3554.
37. Kidd E.A., Siegel B.A., Dehdashti F., et al. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007, 110:1738-1744.
38. Kidd E.A., Siegel B.A., Dehdashti F., et al. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer. Cancer 2010, 116:1469-1475.
39. Grigsby P.W., Malyapa R.S., Higashikubo R., et al. Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 2007, 9:278-283.
40. Airley R.E., Loncaster J., Raleigh J.A., et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. Int J Cancer 2003, 104:85-91.
41. Hedley D., Pintilie M., Woo J., et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 2003, 9:5666-5674.
42. Woelber L., Kress K., Kersten J.F., et al. Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer. BMC Cancer 2011, 11:12.
43. Kirkpatrick J.P., Rabbani Z.N., Bentley R.C., et al. Elevated CAIX expression is associated with an increased risk of distant failure in early-stage cervical cancer. Biomark Insights 2008, 3:45-55.
44. Yoo C.W., Nam B.H., Kim J.Y., et al. Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome. Radiol Oncol 2010, 5:101.
45. Yin M., Yan J., Martinez-Balibrea E., et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: A systemic review and meta-analysis. Clin Cancer Res 2011, 17:1632-1640.
46. Hasegawa K., Kato R., Torii Y., et al. The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma. Int J Gynecol Cancer 2011, 21:1479-1485.
47. Gaffney D.K., Haslam D., Tsodikov A., et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56:922-928.
48. Iida K., Nakayama K., Rahman M.T., et al. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. Br J Cancer 2011, 105:420-427.
49. Eijsink J.J., Noordhuis M.G., ten Hoor K.A., et al. The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer. Hum Pathol 2010, 41:1735-1741.
50. Noordhuis M.G., Eijsink J.J., Ten Hoor K.A., et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 2009, 15:7389-7397.
51. Kurtz J.E., Hardy-Bessard A.C., Deslandres M., et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. Gynecol Oncol 2009, 113:16-20.
52. Chan Y.M., Ng T.Y., Ngan H.Y., et al. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: Is it cost-effective?. Gynecol Oncol 2002, 84:7-11.
53. Zanagnolo V., Minig L.A., Gadducci A., et al. Surveillance procedures for patients for cervical carcinoma: A review of the literature. Int J Gynecol Cancer 2009, 19:306-313.
54. Kim J.Y., Park S., Nam B.H., et al. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. J Clin Oncol 2009, 27:5088-5093.
55. Wang C.C., Lai C.H., Huang H.J., et al. Clinical effect of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78:1111-1120.
56. Harima Y., Sawada S., Nagata K., et al. Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2002, 52:1345-1351.
57. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
58. Smeets S.J., Braakhuis B.J., Abbas S., et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006, 25:2558-2564.
59. Westra W.H., Taube J.M., Poeta M.L., et al. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008, 14:366-369.
60. Zujewski J.A., Kamin L. Trial assessing individualized options for treatment for breast cancer: The TAILORx trial. Future Oncol 2008, 4:603-610.
61. Ross J.S., Hatzis C., Symmans W.F., et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008, 13:477-493.
62. Choi Y.W., Kim Y.W., Bae S.M., et al. Identification of differentially expressed genes using annealing control primer-based GeneFishing in human squamous cell cervical carcinoma. Clin Oncol (R Coll Radiol) 2007, 19:308-318.
63. Grigsby P.W., Watson M., Powell M.A., et al. Gene expression patterns in advanced human cervical cancer. Int J Gynecol Cancer 2006, 16:562-567.
64. Klopp A.H., Jhingran A., Ramdas L., et al. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. Int J Radiat Oncol Biol Phys 2008, 71:226-236.
65. Weidhaas J.B., Li S.X., Winter K., et al. Changes in gene expression predicting local control in cervical cancer: Results from Radiation Therapy Oncology Group 0128. Clin Cancer Res 2009, 15:4199-4206.
66. Lando M., Holden M., Bergersen L.C., et al. Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet 2009, 5:e1000719.
67. Hu X., Schwarz J.K., Lewis J.S., et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010, 70:1441-1448.